SPRIM Global Investments and OneIM Announce $300 Million Joint Venture to Boost Clinical Trial Funding

Overview

On March 11, 2025, SPRIM Global Investments (SGI), a leading global investment firm specializing in clinical-stage life sciences, and One Investment Management (OneIM) announced a significant joint venture valued at $300 million. This collaboration aims to accelerate funding for clinical trials, bolstering the development of new medical therapies.

The Purpose of the Partnership

The primary goal of this joint venture is to enhance SGI's specialized financing platform, TrialCap. This innovative solution is designed to support clinical trials from phase 1 to phase 3. With over two decades of industry expertise, TrialCap provides flexible financial support to biotechnology and medical technology companies. This financing is critical in helping these companies advance groundbreaking therapies and hasten their market entry.

Michael Shleifer, co-founder and managing partner of SGI, emphasized the mission of this collaboration, stating, "Our aim is to eliminate financial barriers that hinder biotechnology and medical tech companies from focusing on research and development. By collaborating with OneIM, we significantly expand our capacity to deliver essential financing solutions that fuel innovation in life sciences."

Insights from OneIM

Matt Ross, a partner at OneIM, also shared his enthusiasm for this partnership. He noted, "We see tremendous opportunities in the life sciences sector and are excited to work with SGI, a proven firm with deep insights into the healthcare ecosystem and a solid portfolio of opportunities. We look forward to accelerating the growth of this platform alongside Michael and his team."

About SPRIM Global Investments

Founded in 2008, SPRIM Global Investments has positioned itself as a private investment firm specializing in clinical-stage life sciences and pharmaceutical services. SGI's innovative investment model offers impactful and flexible financing to high-potential biotech companies worldwide, thus supporting the advancement of clinical trials and expediting the development of life-changing treatments. Their official website is sprim.net.

About One Investment Management

OneIM is a global alternative investment manager that invests across the entire capital structure. The firm focuses on creating long-term value by collaborating with leading partners and management teams. Established in 2022, OneIM manages $7 billion in assets and operates from offices in Abu Dhabi, London, Tokyo, and New York. More information about their investment approach can be found on their website oneimgroup.com.

Conclusion

This $300 million joint venture represents a critical step forward in the financing landscape for clinical trials, fostering innovation and supporting the next generation of medical breakthroughs. As SGI and OneIM embark on this journey together, they aim to reshape the dynamics of clinical research funding and contribute positively to the advancement of medical science.